Review Article
Proresolving Lipid Mediators: Endogenous Modulators of Oxidative Stress
Table 3
SPMs in ROS-mediated chronic inflammatory diseases.
| SPM | Diseases | References |
| LXA4 | Ischemia/reperfusion | [31–33] | LXA4 | Alzheimer’s disease | [42] | LXA4 | Arthritis | [43] | LXA4 | Asthma | [44] | LXA4 | Inflammatory bowel disease | [47] | LXs | Diabetes | [45] | LXs | Cardiovascular diseases | [46] | RvE1 | Inflammatory bowel disease | [6] | RvE1 | Cardiovascular diseases | [6, 46] | RvD1 | COPD and lung ischemia/reperfusion | [10, 65, 67, 68, 75] | RvD2 | Lung ischemia/reperfusion | [75] | RvD1 | Atherosclerosis | [46] | MaR1 | Lung ischemia/reperfusion | [66, 82, 85] | MaR1 | Cardiovascular diseases | [46, 79, 80] | MaR1 | Diabetes | [84] | PD1 | Diabetes | [92] | PD1 | Cardiovascular diseases | [46, 78] | PD1 | Neurodegenerative diseases | [89–91] |
|
|